“Tango Therapeutics is downsizing by 20%, laying off around 30 employees, as per a Tuesday report from BioPharma Dive.
In a statement to the publication, CEO Barbara Weber pointed to the “extremely challenging financial markets” as a reason for the cuts, adding that they will help Tango lower its expenditures related to preclinical research. “We, like so many others, have been forced to take steps to extend our cash runway,” she said. Tango had 155 employees at the end of 2024, as per its 10-K filing.”
